News
The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and ...
RSV is the leading cause of hospitalization in US infants, and in August 2023, the CDC’s vaccine advisory group recommended ...
With the approach of fall likely bringing the usual uptick in respiratory illness, the provincial government is boosting its ...
Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why SNY stock is a strong buy.
Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.
The company also records Beyfortus product sales from products supplied to partner Sanofi under the V&I Therapies segment. AstraZeneca’s Key Oncology Drugs Beat Estimates ...
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. Learn more on MRNA stock here.
Officials estimated that 228 fewer babies younger than 3 months older were hospitalized for serious RSV infection during the peak of the season, a number they hope will increase as more women are ...
15d
MedPage Today on MSNRFK Jr. Quietly Endorses Flu Vaccine for Kids and Adults
HHS Secretary Robert F. Kennedy Jr. last month quietly endorsed recommendations from his handpicked vaccine advisors that everyone in the U.S. ages 6 months and older receive a flu shot for the ...
If approved, Beyfortus would become the first and only single-dose, passive immunisation for a broad infant population, including those born healthy, at term or preterm, or with specific health ...
In RSV, Sanofi is represented by Beyfortus, an FDA-approved antibody drug that works like a vaccine, providing infants and young children protection from the respiratory pathogen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results